US 9932593
Compositions and methods for inhibiting expression of CD274/PD-L1 gene
granted A61KA61K31/713A61P
Quick answer
US patent 9932593 (Compositions and methods for inhibiting expression of CD274/PD-L1 gene) held by Alnylam Pharmaceuticals, Inc. expires Mon Mar 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue Apr 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 12
- CPC classes
- A61K, A61K31/713, A61P, A61P31/00, A61P31/04